Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
i think we are all missing a trick here
No idea on this share but liked the RNs,good luck everyone
Thanks TQ. I’m surprised we haven’t heard anything more since then
https://www.youtube.com/watch?v=sRP1HeuaNL0
Found the link, go to 44 mins.
PDS Biotech Announces Exclusive Global License Agreement for Investigational IL-12 Tumor-Targeted Cytokine from Merck KGaA, Darmstadt, Germany.
PDS Biotech bolsters immuno-oncology portfolio with a clinical-stage product synergistic with its Versamune® platform.
FLORHAM PARK, N.J., Jan. 03, 2023 (GLOBE NEWSWIRE)
Around May-June.
TQ what was the approximate date of the webinar that suggested this please?
In one of the webinars I recall the management saying the CE marking for the Covid test is a few weeks away but I don’t recall seeing any follow up on that.
We had an annual update on the 6th Jan this year from ProAxis.
7 products for sale, doing funding rounds and want to expand into the USA.
Elephant in the room is their abysmal sales of £100K in the last accounts?!
With Covid coming back in to the headlights it would be good to know what is happening since this update in May.
ProAxsis has completed the development and validation of the AstraZeneca COVID-19 antibody test with "impressive performance evaluation results."
In June 2021 ProAxsis entered into an exclusive licensing agreement with the global biopharmaceutical company AstraZeneca, under which ProAxsis took responsibility for completing the development, validation and global commercialisation of a SARS-CoV-2 (the virus associated with COVID-19) serology ELISA (enzyme-linked immunosorbent assay).
Huge potential and hopefully breaking the years high soon.
Long may it continue. PDSB finished up 13%.
Today PDS is trading at $12.04/share valuing it at $344m and NSCI's 4.72% at £13.5m vs today's market cap for NSCI of £18m (total)
Yet according to WH Ireland PDS is only 26% of NSCI's portfolio (26% of £18m is £4.5m). So ignoring all other parts of the portfolio today's price suggests a £9m upside or 38.2p upside to the share price.
PDS FORECAST
https://www.nasdaq.com/market-activity/stocks/pdsb/analyst-research
Taking the average of the analysts and the future price of $17/share this suggests a 29% upside to PDS which is a further 11p per share upside.
So NSCI should be at £1.12 - £1.25 based on PDS's value, assuming that the rest of the portfolio is already fairly valued (which of course it isn't). The Phase 2 anecdotal evidence of 18 months life extension for people with HPV advanced cancers is the reasons for yesterdays and today's jump.
Slightly pointing out the obvious that this is a Nasdaq publicly listed share so theoretically NSCI could sell the lot and hand shareholders the proceeds worth 57p a share at today's prices.
GLA
were going the right way
Total radio silence from the BOD on our main investments doesn't help.
Lot's of pussed off share holders who got suckered in at £1.30 and a few at 67p which explains the drip of sales into any rise.
Proaxis have 7 products on the market but they can't be a*sed to update their website to tell anyone. In theory they are looking for outside investors but no idea how that is going.
QBot doing £10M a year run rate but who would know.
Glycotest, god only knows.
Anyway, in the September 22 results assets where £30M with PDSB making up £4M of that.
PDSB is now £14M so the other £26M is in the SP for free.
Ivan and his mate own 55% so maybe the silence is a plan to take private on the cheap?
Either way, we should be above a £1.00 after yesterdays excellent PDSB results.
When PDSB hits $1B market cap or approx $30 a share, our holding will have a cash value of £2.00 a share.
If positive PDSB trial results continue to come in and the FDA engages, there is no reason to believe this won't happen. Remember PDSB owns the whole platform.
The rest of the portfolio is worth another £1.00 a share.
Should be an interesting year!
Should've been "little out"
I think your maths is out a little there, I make it just short of 13m of our map, correct me if I'm wrong.
That didn't take long.
Twitter on fire with PDSB and quite a few mentions of NSCI as a way in.
Massive volume of 3M and some really bullish option positions being taken.
Up 25% so NSCI now worth PDSB and cash.
The other £25M of assets in there for free.
PDSB doing really well today.
Overall survival = OS
Median OS is 21 months in 29 checkpoint inhibitor refractory patients who received the triple combination. The reported historical median OS in patients with CPI refractory disease is 3-4 months.
In CPI naïve subjects, 75% remain alive at a median follow-up of 27 months. As a result, median OS has not yet been reached. Historically median OS for similar patients with platinum experienced CPI naïve disease is 7-11 months.
Xmas email from QBot.
Note the 150 installations a month. Normal quote is more than £5K so we are looking at approx £10M T/O a year going forward!
Hope all is well with you.
On behalf of the Q-Bot team, we wish you and your team a very happy Christmas and New Year. We hope that you are able to spend some quality time with loved ones.
It's been a real pleasure working with you throughout 2022 (as always!), improving warmth in people’s home and tackling climate change. Q-Bot's underfloor insulation measure is now being installed in over 150 homes every month, and this number continues to grow. Q-Bot works with over 50 registered social providers, a network of accredited installers, managing agents and private homeowners to significantly reduce the demand for heat in domestic properties.
Thank you for all your support and your continued engagement. We hope to enjoy more of the same in 2023 and beyond.
Wishing you a great Christmas and a wonderful New Year.
With many thanks and festive wishes.
The Q-Bot Team
Thank you to
@Global_H_Pharma
who have awarded SageTech Medical the title of 'Most Environmentally-Conscious #Medical Technology Developer' in their 2023 Global Excellence Awards!
You can see our listing here:
https://ghp-news.com/issues/q4-2022/64/
#GHP #anaesthesia #sustainable
PDS up 4.4% again. Seems to be on a solid volume uptrend